Cohera Medical Receives FDA’s Approval for its TissuGlu Surgical Adhesive
Cohera Medical, Inc., a leading innovator and developer of surgical adhesives and sealants, announced that the U.S. Food and Drug Administration (FDA) has approved its TissuGlu Surgical Adhesive. The approval allows the Company to begin commercial distribution of TissuGlu in the United States.
TissuGlu is the first tissue adhesive for internal use approved by the FDA in the United States. TissuGlu is approved to adhere tissue layers and close dead space in abdominoplasty procedures. In clinical trials, surgeons were able to eliminate the need for post-surgical drains by using TissuGlu, reducing the need for invasive treatments for their abdominoplasty patients, and improving the patient recovery process. The PMA supports the safety and effectiveness of TissuGlu as an alternative to the use of closed suction drains.
“The FDA’s approval of the first synthetic adhesive for internal use will help some abdominoplasty patients get back to their daily routine after surgery more quickly than if surgical drains had been inserted,” said William Maisel, M.D., M.P.H., Deputy Director for science at FDA’s Center for Devices and Radiological Health.
The primary clinical data supporting the FDA approval was from a 130 patient study where half of the participants received drains and the other half received TissuGlu and no drains. The study results showed that 73 percent of participants who received TissuGlu required no postoperative interventions to manage postoperative fluid. Study participants who received TissuGlu without drains were generally able to return to most daily activities such as showering, climbing stairs, and resuming their usual routines sooner than those who had drains.
“FDA approval of TissuGlu is the mos
本站所有信息与内容，版权归原作者所有。网站中部分新闻、文章来源于网络或会员供稿，如读者对作品版权有疑议，请及时与我们联系，电话：025-85303363 QQ：2402955403。文章仅代表作者本人的观点，与本网站立场无关。转载本站的内容，请务必注明"来源：林中祥胶粘剂技术信息网（www.adhesive-lin.com）".
加载中...
